HUTCHMED (China) Limited - ADR
$10.96
$0.28
(2.62%)
As on 12-Jun-2026 16:01EDT
Market cap
$1,885 Mln
Revenue (TTM)
$602 Mln
P/E Ratio
4.1
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.2
-
Debt to Equity
0.1
-
Book Value
$7.1
-
EPS
$2.6
-
Face value
--
-
Shares outstanding
171,950,364
10 Years Aggregate
CFO
$-443.93 Mln
EBITDA
$-1,210.77 Mln
Net Profit
$-952.44 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
HUTCHMED (China) - ADR
| -17.8 | -14.8 | -24.8 | -36.1 | -2.7 | -18.5 | -2.4 |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
HUTCHMED (China) - ADR
| -7.5 | -20.3 | 22.5 | -57.9 | 9.6 | 27.7 | 8.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
HUTCHMED (China) - ADR
|
11.0 | 1,884.6 | 550.0 | 458.1 | -3.3 | 45.9 | 4.1 | 1.5 |
| 893.5 | 55,840.5 | 6,583.9 | 2,003.3 | 14.7 | 29.9 | 39.7 | 7.6 | |
| 17.4 | 1,030.7 | 0.0 | -167.9 | -- | -128.7 | -- | 5.0 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 25.1 | 15,397.5 | 3,900.9 | 821.0 | 23.5 | 14.4 | 19.1 | 2.7 | |
| 12.8 | 904.4 | 369.4 | 12.3 | 7.5 | 5 | 67.4 | 3.4 | |
| 2.8 | 501.2 | 4.0 | -198.4 | -4,917.6 | -166.3 | -- | 6.6 | |
| 17.3 | 424.0 | 4.7 | -109.7 | -- | -30.2 | -- | 1.4 | |
| 5.4 | 507.8 | 156.3 | -138.0 | -16.7 | -121.5 | -- | 5.8 | |
| 17.1 | 1,917.9 | 453.3 | -178.1 | -38.4 | -25.1 | -- | 2.9 |
Shareholding Pattern
View DetailsAbout HUTCHMED (China) - ADR
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides... Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong. Read more
-
Executive Chairman
Mr. Chi Keung To ACGI, B.Sc., M.B.A.
-
Executive Chairman
Mr. Chi Keung To ACGI, B.Sc., M.B.A.
-
Headquarters
Hong Kong
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for HUTCHMED (China) - ADR
What is the current share price of HUTCHMED (China) Limited - ADR Today?
The share price of HUTCHMED (China) Limited - ADR is $10.96 (NASDAQ) as of 12-Jun-2026 16:01 EDT. HUTCHMED (China) Limited - ADR has given a return of -2.65% in the last 3 years.
What is the current PB & PE ratio of HUTCHMED (China) Limited - ADR?
The P/E ratio of HUTCHMED (China) Limited - ADR is 4.14 times as on 12-Jun-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
5.08
|
1.88
|
|
2024
|
66.70
|
3.31
|
|
2023
|
30.63
|
4.23
|
|
2022
|
-6.92
|
4.09
|
|
2021
|
-30.86
|
6.09
|
What is the 52 Week High and Low of HUTCHMED (China) Limited - ADR?
The 52-week high and low of HUTCHMED (China) Limited - ADR are Rs 19.50 and Rs 10.43 as of 14-Jun-2026.
What is the market cap of HUTCHMED (China) Limited - ADR?
HUTCHMED (China) Limited - ADR has a market capitalisation of $ 1,885 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in HUTCHMED (China) Limited - ADR?
Before investing in HUTCHMED (China) Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.